Ed Silverman, for STAT, reports on the continuing struggles of state governments to reign in pharmaceutical costs in the wake of the failed efforts in California. “Nearly a dozen state legislatures around the country have introduced bills that would either require drug makers to justify their pricing or provide detailed information on their costs in hopes that such transparency would slow rising prices.”
